Press Releases

TAFALGIE THERAPEUTICS Announces First Dose Escalation Data From TAFAFIRST, a Phase 1 Clinical Trial Evaluating TT5, a first-in-class Non-Opioid Treatment For Pain

TAFALGIE THERAPEUTICS Announces First Dose Escalation Data From TAFAFIRST, a Phase 1 Clinical Trial Evaluating TT5, a first-in-class Non-Opioid Treatment ... Show more

First Press Release

Tafalgie Therapeutics to benefit from the EIC Accelerator Program We are proud to announce that Tafalgie Therapeutics is one of ... Show more
Visit our contact page